(For other news from the Reuters Health Summit, click on http://today.reuters.com/summit/SummitInfo.aspx?name=HealthSummit06&pid=500) NEW YORK, Nov 8 (Reuters) - GlaxoSmithKline Plc <GSK.L> hopes to win new orders from two big countries for its bird flu vaccine for humans by the year-end, fueling substantial sales of the product in 2007, its chief executive said on Wednesday. So far, Switzerland and an unnamed small Asian country have placed orders for the pre-pandemic H5N1 shot -- which has yet to win final regulatory approval -- but governments of several larger countries are in negotiations. "I think that between now and Christmas we are going to hear from a couple of important countries," Jean-Pierre Garnier told the Reuters Health Summit in New York via a telephone interview from London. Glaxo could next year produce more than 100 million doses of the vaccine, which is designed to immunize people against a future pandemic flu strain and will probably sell for between 7 and 8 euros ($8.94-$10.22) per dose, he added.
